Jane Koh

A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma

Winnie Yeo, Tony Mok, Benny Zee et al. · JNCI Journal of the National Cancer Institute · 2005 · 589 citations · Full text

Medicine, Oncology, Pharmacology +14

High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma

Henry Lik‐Yuen Chan, Chi‐Hang Tse, Frankie Mo et al. · Journal of Clinical Oncology · 2008 · 306 citations

Medicine, Genetics, Oncology +17

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

W.J. Lee, J.L. Lee, S.E. Chang et al. · British Journal of Dermatology · 2009 · 236 citations

Medicine, Oncology, Pharmacology +14

TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance

Nathalie Wong, Winnie Yeo, Wai‐Lap Wong et al. · International Journal of Cancer · 2008 · 196 citations · Full text

Medicine, Molecular Biology, Oncology +17

Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group

Winnie Yeo, Hyun Cheol Chung, Stephen L. Chan et al. · Journal of Clinical Oncology · 2012 · 195 citations · Full text

Medicine, Oncology, Pharmacology +17